Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cuprina Holdings (Cayman)CUPR -2.90%10 Cash-to-Debt is 6.46 as of Dec. 2025, which is 110% above its 10-year median of 3.07. GuruFocus rates CUPR with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Cuprina Holdings (Cayman) ranks better than 69.49% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cuprina Holdings (Cayman)'s cash to debt ratio for the quarter that ended in Dec. 2025 was 6.46.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cuprina Holdings (Cayman)could pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Cuprina Holdings (Cayman)'s Cash-to-Debt or its related term are showing as below:
CUPR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28 Med: 3.07 Max: 6.46
Current: 6.46
During the past 5 years, Cuprina Holdings (Cayman)'s highest Cash to Debt Ratio was 6.46. The lowest was 0.28. And the median was 3.07.
CUPR's Cash-to-Debt is ranked better than 69.49% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 1.69
vs CUPR: 6.46
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cuprina Holdings (Cayman) Cash-to-Debt Related Terms
Cuprina Holdings (Cayman) Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CUPR vs MHUAF, FEMY, UEEC: Cash-to-Debt Comparison
For the Medical Instruments & Supplies subindustry, Cuprina Holdings (Cayman)'s Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cuprina Holdings (Cayman) Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cuprina Holdings (Cayman)'s Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cuprina Holdings (Cayman)'s Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cuprina Holdings (Cayman) (CUPR) has a Cash-to-Debt of 6.46 as of Dec. 2025. This is 110% above median its historical median of 3.07. Over the past decade, Cuprina Holdings (Cayman)'s Cash-to-Debt has ranged from 0.28 to 6.46. According to the industry distribution chart, Cuprina Holdings (Cayman) ranks #259 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 30.5%.
Is Cuprina Holdings (Cayman)'s Cash-to-Debt too high?
Cuprina Holdings (Cayman)'s current Cash-to-Debt of 6.46 is 110% above median its 10-year median of 3.07. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 6.46. The Medical Devices & Instruments industry median Cash-to-Debt is 1.69. Cuprina Holdings (Cayman)'s value of 6.46 is 282.2% above this industry median. Based on the distribution chart, Cuprina Holdings (Cayman) ranks #259 out of 849 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Cuprina Holdings (Cayman) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Cuprina Holdings (Cayman)'s Cash-to-Debt compare to MHUAF and FEMY?
According to the Medical Devices & Instruments industry distribution chart, Cuprina Holdings (Cayman) ranks #259 out of 849 companies for Cash-to-Debt. This puts Cuprina Holdings (Cayman) in the upper half of its industry. The industry median Cash-to-Debt is 1.69. Cuprina Holdings (Cayman)'s value of 6.46 is 282.2% above this benchmark. Historically, Cuprina Holdings (Cayman)'s own Cash-to-Debt has ranged from 0.28 to 6.46 over the past decade. While the company's 10-year median is 3.07 vs. the industry median of 1.69, Cuprina Holdings (Cayman) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.69, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cuprina Holdings (Cayman)'s current Cash-to-Debt of 6.46 is 282.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cuprina Holdings (Cayman)'s current Cash-to-Debt is 6.46, which is 110% above median its own 10-year median of 3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuprina Holdings (Cayman) stock overvalued right now?
Cuprina Holdings (Cayman) (CUPR) has a current Cash-to-Debt of 6.46. The current Cash-to-Debt is 6.46, which is 110% above median its 10-year median of 3.07 and 282.2% above the Medical Devices & Instruments industry median of 1.69. Cuprina Holdings (Cayman)'s overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cuprina Holdings (Cayman) (CUPR), the current Cash-to-Debt is 6.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
10GF Score
Get the complete analysis for CUPR
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUPR has been successfully added to your 
